New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies

Francesca Patriarca, Luisa Giaccone, Francesco Onida, Luca Castagna, Barbara Sarina, Vittorio Montefusco, Alberto Mussetti, Nicola Mordini, Elena Maino, Raffaella Greco, Jacopo Peccatori, Moreno Festuccia, Francesco Zaja, Stefano Volpetti, Antonio Risitano, Renato Bassan, Paolo Corradini, Fabio Ciceri, Renato Fanin, Michele BaccaraniAlessandro Rambaldi, Francesca Bonifazi, Benedetto Bruno

Research output: Contribution to journalArticlepeer-review


Introduction: Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to ‘smartly’ combine ‘targeted drugs and cell therapies’ in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.
Original languageEnglish
Pages (from-to)821-836
Number of pages16
JournalExpert Opinion on Biological Therapy
Issue number7
Publication statusPublished - Jul 3 2017


  • Allogeneic stem cell transplantation
  • graft-versus-tumor
  • monoclonal antibodies
  • new drugs
  • targeted therapy


Dive into the research topics of 'New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies'. Together they form a unique fingerprint.

Cite this